Use of human cells of myeloid leukaemia origin for expression of antibodies
AssigneeGlycotope GmbH
InventorsSteffen Goletz, Antje Danielczyk, Hans Baumeister, Renate Stahn, Anja Löffler, Lars Stöckl
Life of this patent
Estimating the term…
Abstract
The invention relates to a method for producing a protein molecule composition having a defined glycosylation pattern, comprising (a) introducing in a host cell which is an immortalized human blood cell at least one nucleic acid encoding at least a part of said protein; and (b) culturing said host cell under conditions which permit the production of said protein molecule composition; and (c) isolating said protein molecule composition.
Claims46
A method for producing a protein molecule composition, comprising
- (a) introducing in a host cell which is an immortalized human blood cell at least one nucleic acid encoding said protein;
- and
- (b) culturing said host cell under conditions which permit the production of said protein molecule composition;
- and
- (c) isolating said protein molecule composition;
- wherein the host cell is selected from the group consisting of GT-2×[DSM ACC 2858], NM-H9D8 [DSM ACC 2806], NM-H9D8-E6 [DSM ACC 2807], and NM H9D8-E6Q 12 [DSM ACC 2856].
An immortalized human blood cell selected from the group consisting of GT-2×[DSM ACC 2858], NM-H9D8 [DSM ACC 2806], NM-H9D8-E6 [DSM ACC 2807], and NM-H9D8-E6Q12 [DSM ACC 2856].
A method for producing an antibody molecule composition comprising
- (a) introducing at least one nucleic acid encoding said antibody into a host cell;
- wherein the host cell is an immortalized human blood cell;
- (b) culturing said host cell under conditions which permit the production of said antibody molecule composition;
- and
- (c) isolating said antibody molecule composition;
- wherein the antibody is selected from the group consisting of
- an antibody which binds a MUC1 epitope comprising the amino acid sequence DTR of the extracellular tandem repeat region;
- Cetuximab or a variant thereof, binding the same epitope as Cetuximab;
- and
- a fragment of anyone of these antibodies comprising the binding region of said antibody;
- and
- wherein the host cell is selected from the group consisting of K562, NM-F9 [DSM ACC 2606], NM-D4 [DSM ACC 2605], GT-2×[DSM ACC 2858], NM-H9D8 [DSM ACC 2806], NM-H9D8-E6 [DSM ACC 2807], and NM-H9D8-E6Q12 [DSM ACC 2856].
Dependencies are inferred from the claim text.